IBM has partnered with pharmaceutical giant Pfizer to design an artificial intelligence (AI) model to predict the eventual onset of the neurological disease seven years before symptoms appear.
Alzheimer's is currently incurable and is often diagnosed too late to prevent it from accelerating. Symptoms for the disease include the gradual degradation of memory, confusion, and difficulty in completing once-familiar daily tasks.
Published in The Lancet eClinical Medicine, the researchers used small samples of language data from clinical verbal tests provided by the Framingham Heart Study, a long-term study that has been tracking the health of more than 5,000 people and their families since 1948, to train the AI models.
The AI model's ability was then verified against data samples from a group of healthy individuals who eventually did and did not develop the disease later in life. For example, if the AI model analysed a speech sample from a participant at the age of 65 and predicted they would develop Alzheimer's by the age of 85, researchers were then able to check records to determine if and when a diagnosis had actually occurred.
Read more: How AI can help diagnose neurological disease[1] (TechRepublic)
According to Big Blue, the outcome of this research was significantly better than predictions based on clinical scales, a prediction based on other available biomedical data from a patient, as that only had an accuracy rate of 59%.
IBM added that unlike past studies, this new one focused on individuals that started to show symptoms or had a genetic history associated with the disease and only examined healthy individuals with no other risk factors.
"In partnership with our colleagues from Pfizer, we saw the potential to develop AI models which -- if continued to